Sera Prognostics, Inc. (SERA)
| Market Cap | 78.29M |
| Revenue (ttm) | 81,000 |
| Net Income (ttm) | -31.93M |
| Shares Out | 39.14M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,069 |
| Open | 2.000 |
| Previous Close | 2.000 |
| Day's Range | 1.980 - 2.120 |
| 52-Week Range | 1.370 - 4.090 |
| Beta | 1.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 6, 2026 |
About SERA
Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive an... [Read more]
Financial Performance
In 2025, Sera Prognostics's revenue was $81,000, an increase of 5.19% compared to the previous year's $77,000. Losses were -$31.93 million, -2.95% less than in 2024.
Financial StatementsNews
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026
SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...
Sera Prognostics Earnings Call Transcript: Q4 2025
2025 saw pivotal progress with PRIME study publication, expanded payer and provider engagement, and disciplined financial management. Revenue remains modest, but strong cash reserves and a focused commercial strategy position the company for gradual adoption and growth.
SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026
SALT LAKE CITY, March 4, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
Sera Prognostics Transcript: TD Cowen 46th Annual Health Care Conference
Preterm birth remains a major unmet need, with new trial data showing significant clinical and economic benefits from a bundled intervention. Expansion efforts are focused on Medicaid and commercial payers across more states, with guideline inclusion and provider education underway. International growth is planned for Europe.
SERA PROGNOSTICS TO PRESENT AT TD COWEN 46th ANNUAL HEALTH CARE CONFERENCE
SALT LAKE CITY, Feb. 17, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
Sera Announces Publication Acceptance for PRIME Study
The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year SALT LAKE CITY , Nov. 24, 2025 /P...
Sera Prognostics Earnings Call Transcript: Q3 2025
Q3 2025 saw continued commercial progress with the first Medicaid pilot live, expanding payer engagement across 13 states, and imminent PRIME study publication. Financials showed stable expenses, a slight net loss improvement, and strong cash reserves.
SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
SALT LAKE CITY , Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025
SALT LAKE CITY , Oct. 30, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...
Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer
SALT LAKE CITY , Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
Sera Prognostics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A proteomics-based test for predicting preterm birth was showcased, demonstrating superior efficiency and clinical outcomes compared to traditional methods. Commercialization is underway in targeted states, with strong clinical validation, payer engagement, and digital outreach.
SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE
SALT LAKE CITY , Aug. 28, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...
Sera Prognostics Earnings Call Transcript: Q2 2025
Q2 2025 saw continued commercial expansion, strategic leadership hires, and progress toward PRIME Study publication. Revenue declined year-over-year, but operating expenses remained flat and cash reserves are strong, supporting growth initiatives and European market entry.
SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
SALT LAKE CITY , Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2025 Financial Results on August 6, 2025
SALT LAKE CITY , July 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy bioma...
SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
SALT LAKE CITY , May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
Sera Prognostics Transcript: RBC Capital Markets Global Healthcare Conference 2025
A new lab-developed test for preterm birth prediction, supported by strong clinical data and payer partnerships, is targeting a $3B+ market with rapid Medicaid and commercial adoption. The company is well-funded, scaling operations, and expanding its pipeline in women's health.
SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE
SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER
Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY , May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SER...
Sera Prognostics Earnings Call Transcript: Q1 2025
Q1 2025 saw initial revenue growth and stable losses as commercial expansion began, leveraging PRIME Study results and targeting Medicaid pilots in key states. Updated ACOG guidelines and rising maternal mortality rates support the need for risk-based prenatal care.
SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
SALT LAKE CITY , May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025
SALT LAKE CITY , April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biom...
Sera Prognostics Earnings Call Transcript: Q4 2024
2024 saw pivotal clinical results, a successful capital raise, and strategic commercial expansion, with PRIME study data showing significant reductions in neonatal risks. Cash runway extends through 2028, with 2025 focused on commercialization and evidence-building.
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN
SALT LAKE CITY , March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomar...